The Catalan industrial sector received €1.365 billion of direct foreign investment in 2013, the highest amount since 2005, according to Barcelona’s Chamber of Commerce. This represents 52% of the total foreign investment in...
Víctor Grífols, the President and part owner of the Catalan pharmaceutical company Grífols – which is one of the world leaders for blood-derivate products – has advised the President of the Catalan Government,...
The profits of Catalan pharmaceutical company Grífols in 2013 grew by 34.6% over the previous year, reaching €345.6 million, as reported by the multinational to the Spanish Stock Exchange Regulation Authority...
The management of Barcelona-based Almirall pharmaceutical multinational and trade unions have signed an agreement on Monday, reducing the initially planned number of laid-off employees from 250 to 180. The document, which has...
The Catalan Institute of Oncology (ICO) and Roche pharmaceutical company have signed an agreement stating that the Catalan public institute will pay for treatments against cancer depending on clinical results adapted to each specific patient....
Catalan pharmaceutical company Almirall has announced on Tuesday it will buy Aqua Pharmaceuticals, an American company specialised in dermatological treatments. The $328 million transaction reflects the Catalan multinational’s strategy...
The Catalan pharmaceutical company Grífols and Barcelona’s Alzheimer Treatment&Research Center of Fundació ACE – a family charity – have announced that they will run tests of a vaccine against this...
Biocat, the organisation responsible for coordinating and promoting the life sciences sector in Catalonia, presented the 2013 Biocat report in Barcelona. Since its creation in 2006, by the Catalan Government and the Barcelona City Council,...
Catalan pharmaceutical company Grífols has purchased 21.3% of Belgian biotech company TiGenix for €12 million through the subscription of a capital increase. TiGenix is a leading company in the field of cell...
